Open AccessA Case of Cutaneous Leishmaniasis Responding to Systemic Liposomal Amphotericin B Treatment
Author(s) -
Esra Çakmak Taşkın,
Hatice Büşra Kütükçü,
Hatice Kübra Konca,
Gül Arga,
Halil Özdemir,
Bengü Nisa Akay,
Ergın Çıftçı,
Erdal Ïnce
Publication year - 2020
Publication title -
çocuk enfeksiyon dergisi
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.122
H-Index - 9
eISSN - 1308-5271
pISSN - 1307-1068
DOI - 10.5578/ced.202069
Subject(s) - meglumine antimoniate , cutaneous leishmaniasis , amphotericin b , leishmaniasis , medicine , leishmania , tropical disease , dermatology , visceral leishmaniasis , meglumine , pharmacology , antifungal , disease , immunology , parasite hosting , world wide web , computer science , magnetic resonance imaging , radiology
Leishmania is a vector-induced endemic tropical disease caused by protozoans. The most common cutaneous, mucosal and visceral forms are the cutaneous form. The main drugs in treatment are pentavalent antimony compounds, but their side effects create limitation of use. Local antimony compounds are used primarily in the treatment of cutaneous leishmaniasis. In some cases, alternative treatment modalities are required due to insufficient response to local treatment. Systemic amphotericin B treatment is one of the alternative treatments. In a patient who developed cutaneous Leishmania at 21 months and who did not respond with local meglumine antimoniate therapy, a total of 21 mg/kg dose of systemic amphotericin B was given intermittently and successful results were obtained.